Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Biotechnologie

Ms. Sarah  Cavanaugh

Senior Vice President of Corporate Affairs & Administration

Mr. Freddy A. Jimenez Esq.

Senior Vice President & General Counsel

Dr. Tibor  Keler Ph.D.

Founder, Chief Scientific Officer & Executive Vice President

Ms. Elizabeth  Crowley

Chief Product Development Officer & Senior Vice President

Dr. Ronald A. Pepin

Chief Business Officer & Senior Vice President

Mr. Anthony S. Marucci M.B.A.

Founder, President, Chief Executive Officer & Director

Mr. Sam  Martin

Senior Vice President, Chief Financial Officer, Secretary & Treasurer

Dr. Diane C. Young M.D.

Senior Vice President & Chief Medical Officer

Dr. Margo  Heath-Chiozzi M.D.

Senior Vice President of Regulatory Affairs

Prof. Joseph P. Schlessinger Ph.D.

Co-Founder & Member of Scientific Advisory Board

Name	Marktkapitalisierung
Sorrento Therapeutics, Inc.	0M
Maravai LifeSciences Holdings, Inc.	0M
Comera Life Sciences Holdings, Inc.	0M
Gubra A/S	0M
CytoTools AG	0M
Hofseth BioCare ASA	0M
Shanghai Haohai Biological Technology Co., Ltd.	0M
Purple Biotech Ltd.	0M

Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. Liste der Konkurrenten

Wichtigste Wettbewerber